FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,385,771 | -53.3% | 137,341 | +3.6% | 0.00% | -60.0% |
| Q3 2022 | $2,970,000 | +87.6% | 132,552 | +107.5% | 0.01% | +150.0% |
| Q2 2022 | $1,583,000 | -36.8% | 63,879 | +1.6% | 0.00% | -33.3% |
| Q1 2022 | $2,506,000 | -9.6% | 62,881 | +32.7% | 0.00% | -25.0% |
| Q4 2021 | $2,773,000 | +44.2% | 47,388 | +46.1% | 0.00% | +33.3% |
| Q3 2021 | $1,923,000 | -62.6% | 32,440 | -45.2% | 0.00% | -50.0% |
| Q2 2021 | $5,141,000 | +38.5% | 59,234 | +31.6% | 0.01% | +20.0% |
| Q1 2021 | $3,711,000 | -73.8% | 45,008 | -71.1% | 0.01% | -50.0% |
| Q4 2020 | $14,176,000 | +323.4% | 155,902 | +77.3% | 0.01% | +100.0% |
| Q3 2020 | $3,348,000 | +21.4% | 87,908 | +9.4% | 0.01% | 0.0% |
| Q2 2020 | $2,758,000 | +19.6% | 80,389 | -13.6% | 0.01% | 0.0% |
| Q1 2020 | $2,306,000 | +27.4% | 93,003 | +0.5% | 0.01% | +66.7% |
| Q4 2019 | $1,810,000 | – | 92,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |